Perrigo Company has launched clobetasol propionate spray, 0.05 per cent, the generic equivalent to Clobex Spray, 0.05 per cent. Perrigo was the first generic filer against this product and it is entitled to 180 days of generic exclusivity. The launch date was agreed upon in a litigation settlement between Perrigo and Galderma Laboratories, L.P.

Clobetasol propionate spray, 0.05 per cent is indicated for the topical treatment of moderate to severe plaque psoriasis affecting up to 20 per cent body surface area in adults 18 years of age or older and 52-week sales of the product were approximately $100 million, according to IMS Health.

Perrigo's chairman, president and CEO Joseph C. Papa stated, "This is another example of our Rx team's commitment to launching difficult to manufacture products. We are excited to market this product and are dedicated to making quality healthcare more affordable for consumers around the globe."

From its beginnings as a packager of generic home remedies in 1887, Perrigo Company plc, headquartered in Ireland, has grown to become a leading global healthcare supplier. Perrigo develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, nutritional products and active pharmaceutical ingredients (API), and receives royalties from Multiple Sclerosis drug Tysabri. The Company is the world's largest manufacturer of OTC healthcare products for the store brand market and an industry leader in pharmaceutical technologies. Perrigo's mission is to offer uncompromised "Quality Affordable Healthcare Products" and it does so across a wide variety of product categories primarily in the United States, United Kingdom, Mexico, Israel and Australia, as well as more than 40 other key markets worldwide, including Canada, China and Latin America.